Antagonistic crosstalk between SIRT1, PARP-1, and -2 in the regulation of chronic inflammation associated with aging and metabolic diseases

다국어 초록 (Multilingual Abstract)

Current studies have indicated the association of chronic sterile inflammation (inflammation in the absence of pathogens) with the pathogenesis of age-related and metabolic diseases. The inflammation is under the control of transcription factor NF-κB through an antagonistic crosstalk between SIRT1, PARP-1, and -2 signaling pathways. The transcriptional activity of NF-κB is increased in various tissues with aging and metabolic abnormalities and is related with various aging and metabolic diseases such as Alzheimer's disease, diabetes, and osteoporosis. Furthermore, NF-κB activation with chronic inflammation is connected with many known life span and metabolic regulators including DNA damage, obesity, SIRT, and PARP. Thus, the crossroads between PARP and SIRT signaling pathways represent efficient therapeutic targets for extending health span without metabolic diseases.

참고문헌 (Reference)

1 Baker RG, "inflammation,and metabolic disease" 13 : 11-22, 2011

2 Lin J, "Transcriptional co-activator PGC-1 alpha drives theformation of slow-twitch muscle fibres" 418 : 797-801, 2002

3 15Houtkooper RH, "The secretlife of NAD+ : an old metabolite controlling new metabolicsignaling pathways" 31 : 194-223, 2010

4 Bai P, "The role of PARP-1 and PARP-2 enzymes inmetabolic regulation and disease" 16 : 290-295, 2012

5 Gross DN, "The role of FoxOin the regulation of metabolism" 27 : 2320-2336, 2008

6 Tornatore L, "The nuclear factor kappa B signaling pathway : integratingmetabolism with inflammation" 22 : 557-566, 2012

7 Krishnakumar R, "The PARP side of the nucleus:molecular actions, physiological outcomes, and clinicaltargets" 39 : 8-24, 2010

8 Brunet A, "Stress-dependent regulation of FOXO transcriptionfactors by the SIRT1 deacetylase" 303 : 2011-2015, 2004

9 Feige JN, "Specific SIRT1 activation mimics low energy levelsand protects against diet-induced metabolic disorders byenhancing fat oxidation" 8 : 347-358, 2008

10 Houtkooper RH, "Sirtuins as regulators ofmetabolism and healthspan" 13 : 225-238, 2012

11 Rajamohan SB, "SIRT1 promotes cell survival understress by deacetylation-dependent deactivation ofpoly(ADP-ribose)polymerase 1" 29 : 4116-4129, 2009

12 Herranz D, "SIRT1 : recent lessons from mousemodels" 10 : 819-823, 2010

13 Pacher P, "Role of poly(ADP-ribose)polymerase 1(PARP-1)in cardiovascular diseases : the therapeuticpotential of PARP inhibitors" 25 : 235-260, 2007

14 Lagouge M, "Resveratrol improves mitochondrialfunction and protects against metabolic disease byactivating SIRT1 and PGC-1alpha" 1147 : 275-282, 2006

15 Liu D, "Preventing NAD(+)depletionprotects neurons against excitotoxicity : bioenergetic effectsof mild mitochondrial uncoupling and caloric restriction" 1147 : 275-282, 2008

16 Masutani M, "Poly(ADP-ribosyl)ation in relation to cancer andautoimmune disease" 62 : 769-783, 2005

17 Szanto M, "Poly(ADP-ribose)polymerase-2 depletion reducesdoxorubicin-induced damage through SIRT1 induction" 92 : 430-438, 2011

18 Pillai JB, "Poly(ADP-ribose)polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reducedSir2alpha deacetylase activity" 280 : 43121-43130, 2005

19 Shevalye H, "Poly(ADP-ribose)polymerase(PARP)inhibition counteracts multiple manifestations of kidneydisease in long-term streptozotocin-diabetic rat model" 79 : 1007-1014, 2010

20 Jagtap P, "Poly(ADP-ribose)polymerase and thetherapeutic effects of its inhibitors" 4 : 421-440, 2005

21 Pang J, "Poly(ADP-ribose)polymerase 1 is involved in glucose toxicitythrough SIRT1 modulation in HepG2 hepatocytes" 112 : 299-306, 2011

22 Qin WD, "Poly(ADP-ribose)polymerase 1 inhibition protects againstlow shear stress induced inflammation" 1833 : 59-68, 2013

23 Pillai JB, "Poly(ADP-ribose) polymerase-1-deficient mice areprotected from angiotensin II-induced cardiac hypertrophy" 291 : H1545-H1553, 2006

24 Bai P, "PARP-2 regulates SIRT1 expression and whole-bodyenergy expenditure" 13 : 450-460, 2011

25 Bai P, "PARP-1 inhibition increases mitochondrial metabolismthrough SIRT1 activation" 13 : 461-468, 2011

26 Rodgers JT, "Nutrient control of glucose homeostasisthrough a complex of PGC-1alpha and SIRT1" 434 : 113-118, 2005

27 Tanno M, "Nucleocytoplasmic shuttling of the NAD+-dependenthistone deacetylase SIRT1" 282 : 6823-6832, 2007

28 Kominsky DJ, "Metabolic shifts inimmunity and inflammation" 184 : 4062-4068, 2010

29 Nicolas L, "Loss of poly(ADP-ribose)polymerase-2 leads torapid development of spontaneous T-cell lymphomas inp53-deficient mice" 29 : 2877-2883, 2010

30 Fong PC, "Inhibition of poly(ADP-ribose)polymerase in tumorsfrom BRCA mutation carriers" 361 : 123-134, 2009

31 Mota RA, "Inhibition of poly(ADP-ribose)polymerase attenuates the severity of acute pancreatitis andassociated lung injury" 85 : 1250-1262, 2005

32 Mangerich A, "Inflammatory and age-relatedpathologies in mice with ectopic expression of humanPARP-1" 131 : 389-404, 2010

33 Muiras ML, "Increasedpoly(ADP-ribose) polymerase activity in lymphoblastoid celllines from centenarians" 76 : 346-354, 1998

34 Hanahan D, "Hallmarks of cancer : the nextgeneration" 144 : 646-674, 2011

35 Liu TF, "Fueling the flame : bioenergy couples metabolism andinflammation" 92 : 499-507, 2012

36 Houtkooper RH, "Exploring the therapeutic spacearound NAD+" 199 (199): 205-209, 2012

37 Tong WM, "DNA strandbreak-sensing molecule poly(ADP-Ribose) polymerasecooperates with p53 in telomere function, chromosomestability, and tumor suppression" 21 : 4046-4054, 2001

38 Canto C, "Crosstalk betweenpoly(ADP-ribose)polymerase and sirtuin enzymes" 34 : 1168-1201, 2013

39 Kolthur-Seetharam U, "Control of AIF-mediated cell death by thefunctional interplay of SIRT1 and PARP-1 in response to DNAdamage" 5 : 873-877, 2006

40 Ford AL, "Climbing STAIRs towards clinical trials witha novel PARP-1 inhibitor for the treatment of ischemicstroke" 1410 : 120-121, 2011

41 Shapiro H, "Ariel A. Macrophages,meta-inflammation, and immuno-metabolism" 11 : 2509-2529, 2011

42 Massudi H, "Age-associated changes in oxidative stress andNAD+ metabolism in human tissue" 7 : e42357-, 2012

43 Underhill C, "A review of PARPinhibitors : from bench to bedside" 22 : 268-279, 2011

44 Luo X, "A one and a two expanding roles forpoly(ADP-ribose)polymerases in metabolism" 13 : 353-355, 2011